QuickCool AB is a medtech company based at Ideon Science Park in Lund, Sweden.
The company has developed a patented brain and body cooling system primarily for sudden cardiac arrest patients, but also for experimental stroke treatment and fever management.
QuickCool’s cooling system is based on a proprietary method. Balloon catheters inserted into the nasal cavity are used to circulate cold saline solution, utilizing the nasal cavity's heat exchanging properties to cool the brain and body.
QuickCool is a young medtech company active in the field of therapeutic cooling as a protective treatment for the brain. The company was founded in 2003 by the professors Anders Lunderquist and Tadeusz Wieloch; senior physician, Fredrik Boris-Möller; economist Lennart Sjölund and perfusionist, Mats Allers.
Research is the basis for QuickCool. The founders’ complementary expertise contributed to the development of innovative medical technology for the rapid treatment of patients in need of therapeutic cooling.
The research began in the late 1980s when Tadeusz Wieloch and Fredrik-Boris Möller were at Lund University, and showed how cooling alleviates brain damage in experimental models for cardiac arrest and stroke. Cooling the brain can prevent many harmful mechanisms triggered by oxygen deprivation arising from critical illnesses such as cardiac arrest and stroke.
Around 2000, the company’s founders began to think about ways to combine the team’s knowledge on brain protective treatment with experience of developing heart-lung equipment for cooling blood and fluids. From 2003 to 2006, a number of pre-clinical tests were conducted to increase understanding of the central principles involved in treatment involving cooling and to show proof-of-principle in animal models for a newly developed method to cool via the nasal cavity. Most of these studies have been published in international research journals. QuickCool’s activities are thus based on solid scientific foundations.
The new knowledge obtained from the pre-clinical tests was the basis for a series of clinical trials both in Sweden and abroad with the aim to optimize the nasal cavity cooling system for human applications. The first clinical trials on cardiac arrest patients took place at Uppsala University Hospital in 2007. From 2007 to 2011, a number of studies were conducted on further developed equipment and the cooling method – everything from advanced volunteer studies using MRI scanning to clinical trials on cardiac arrest, trauma and other intensive care patients in need of cooling treatment. QuickCool participated in the EU project ARISE (2007-2013) and EUROHYP-1 (ongoing). During this period, there was continuous development of the balloon catheter design, and in 2010 a new CE-marked cooling device, ComVic, was introduced. QuickCool’s cooling system has proved to be popular among users, as it is easy to use, does not cover the entire patient with cooling bags and also offers a portable system that delivers continuous cooling throughout the treatment period.
In 2013, the Target Temperature Management (TTM) study was published in the respected research journal, The New England Journal of Medicine. The results from this multi-center study received wide attention, as they showed that cooling for cardiac arrest patients was equally effective at approx. 36°C as it was at 33°C. Cooling to 36°C also avoided a number of potential risks associated with lower temperatures and enabled the treatment of conscious patients (e.g. stroke) who would otherwise be affected by extreme shivering.
QuickCool applied these finding in the development of a compact, portable cooling system. In December 2015, QuickCool was listed on AktieTorget and since then the company has been financed to facilitate the development and launch of a commercial cooling system. The company’s new generation cooling unit offers the simplest and most portable system on the market for cooling at 36°C. The future looks bright for QuickCool’s launch of the QuickCool® SYSTEM in 2018.